DBVT - DBV Technologies: Selloff Provides Attractive Entry Big Upside Ahead Of Expected Drug Approval
Editor's note: Seeking Alpha is proud to welcome Eugene Capital Advisors as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA PREMIUM. Click here to find out more »
About DBV Technologies
DBV Technologies (DBVT) is a French biopharmaceutical firm focused on developing immunotherapies for patients with food allergies. Its product, Viaskin, is an epicutaneous immunotherapy, or EPIT, a patch that delivers the allergen to the immune system through the skin. According to the most recent company